The underlying cause of interstitial cystitis is not fully established, and no specific causative genes have been identified in the certified data for this condition. Current understanding suggests the condition may involve disruption of the bladder epithelial barrier along with complex immune and nervous system interactions, though the precise mechanisms remain under investigation.

Diagnosis of interstitial cystitis is generally based on characteristic clinical symptoms following exclusion of other conditions that produce similar findings. Evaluation may include cystoscopy and bladder examination. Formal diagnostic criteria for this condition have evolved over time and are not universally standardized. The diagnosis requires careful differentiation from urinary tract infections, other urological conditions, and pelvic inflammatory disorders.

Two FDA-approved treatments are available for interstitial cystitis: pentosan polysulfate sodium (Elmiron), approved in 1996, and dimethyl sulfoxide (RIMSO-50), approved in 1978 for intravesical instillation. Pentosan polysulfate sodium is an oral agent thought to act on the bladder lining. Dimethyl sulfoxide is administered directly into the bladder. Additional interventions used in clinical practice include physical therapy, dietary modifications, neuromodulation, and other symptom management strategies. Treatment responses and outcomes vary among individuals.

Interstitial cystitis follows a variable and often chronic course. Symptoms may fluctuate over time, with periods of relative remission and exacerbation. Long-term outcomes differ considerably depending on symptom severity, treatment response, and individual factors.

Interstitial cystitis is an active area of clinical investigation, with numerous ongoing clinical trials evaluating pharmacological agents, behavioral interventions, medical devices, and procedural treatments. Research is also examining potential biomarkers and underlying contributors to the condition. Information on active trials is available at ClinicalTrials.gov.